390 Real world prescribing patterns of dupilumab for atopic dermatitis

The prevalence of atopic dermatitis (AD) in the USA is ∼12% children and ∼7% adults. We conducted a retrospective, observational, cohort study examining prescribing patterns systemic biologic dupilumab for AD using University Colorado Hospital Children’s electronic medical record databases. sought to test hypothesis that this expensive medicine (∼$3.5K/dose https://www.drugs.com/price-guide/dupixent, accessed 1/19/22) might be less commonly prescribed Black Hispanic patients. Study subjects were between ages 4 85 years age as 3/28/2017 (the date was FDA approved treat moderate severe those 12 older). diagnosis inclusion criteria included having at least two diagnoses (defined ICD-10 codes L20, L20.0, L20.8, L20.81, L20.82, L20.84, L20.89, L20.9). Any prescription included. Dupilumab start required on or after 3/28/2017, had occur AD. 267 persons out 7723 meeting received one prescription. Mean (standard deviation) among 47 (22) 57% female. Analysis by patient characteristics revealed following associations (odds ratio [confidence interval] p value): per ten year increment (1.06 [1-1.12] 0.051), female (0.93 [0.73-1.20] 0.59), (2.3 [1.58-3.33] <0.001), (0.79 [0.50-1.19] 0.28). Our preliminary data surprisingly Blacks more likely than other racial ethnic groups our academic health care system. analysis will further explore with severity disease, insurance type, patients who multiple plus another may also treated dupilumab.(e.g. certain cases chronic rhinosinusitis nasal polyps asthma).